ArticleCase reports in pediatrics2025
Severe RSV Infection Occurring at the End of Nirsevimab's Protection Window: A Case Report.
Article in Case reports in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of a five-month-old late preterm infant who developed severe bronchiolitis caused by respiratory syncytial virus, requiring hospitalisation and high-flow nasal cannula support. This occurred 142 days after the infant received a single dose of nirsevimab as part of the regional immunisation campaign, administered on day three of life. The patient had no underlying conditions. PCR testing revealed RSV A and human rhinovirus co-infection. The infant improved with supportive care and was discharged in stable condition after 8 days. This case raises concerns about possible waning immunity near the end of the expected 150-day protection window of nirsevimab, particularly in infants immunised early in the RSV season. Additionally, co-infection with hRV may have contributed to disease severity. Although nirsevimab remains a highly effective preventive tool, this case highlights the potential for waning immunity near the end of the protection window and suggests that ongoing surveillance is essential to optimize immunization strategies, particularly in regions with prolonged RSV seasons.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.